Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 2/20 | 0.54 |
| ▸ | BACE1 | P56817 | 4/20 | 0.51 |
| ▸ | PIM2 | Q9P1W9 | 12/20 | 0.47 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.44 |
| ▸ | PIM1 | P11309 | 3/20 | 0.44 |
| ▸ | PIM3 | Q86V86 | 3/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13067930 | 0.88 | CHEK1 (0.54) | CHEK1BACE1PIM2ACKR3 | |
| SCHEMBL13028201 | 0.88 | BACE1 (0.49) | CHEK1BACE1PIM2PIM1PIM3 | |
| SCHEMBL13028212 | 0.88 | BACE1 (0.48) | CHEK1BACE1PIM2PIM1PIM3 | |
| SCHEMBL13015419 | 0.87 | CHEK1 (0.54) | CHEK1BACE1PIM2ACKR3PIM1 | |
| SCHEMBL13028211 | 0.85 | BACE1 (0.47) | CHEK1BACE1PIM2PIM1PIM3 | |
| SCHEMBL13028217 | 0.84 | CHEK1 (0.74) | CHEK1PIM2PIM1PIM3 | |
| SCHEMBL13028203 | 0.84 | BACE1 (0.51) | CHEK1BACE1PIM2PIM1PIM3 | |
| SCHEMBL13028202 | 0.83 | IRAK4 (0.51) | BACE1PIM2PIM1PIM3 | |
| SCHEMBL13028209 | 0.83 | BACE1 (0.50) | CHEK1BACE1PIM2PIM1PIM3 | |
| SCHEMBL13028198 | 0.83 | BACE1 (0.51) | CHEK1BACE1PIM2PIM1PIM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293747-B2 | Heterocyclic amide compounds as protein kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-10-23 | — | — | US | disclosed |
| US-8293747-B2 | Heterocyclic amide compounds as protein kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-10-23 | — | — | US | disclosed |
| US-20100286135-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS PROTEIN KINASE INHIBITORS | Schering Corporation Patent Department, K-6-1; 1990 (US) | 2010-11-11 | — | — | US | disclosed |
| US-20100286135-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS PROTEIN KINASE INHIBITORS | Schering Corporation Patent Department, K-6-1; 1990 (US) | 2010-11-11 | — | — | US | disclosed |
| WO-2009014637-A2 | HETEROCYCLIC AMIDE COMPOUNDS AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION (US) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286135-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS PROTEIN KINASE INHIBITORS | MTOR, CDK1, MAP3K8 | CHEK1 113/4885BACE1 550/4885PIM2 890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.